Table 2.

Phenotype of NK cells in pre- and posttreatment PBMC compared with the infused cell populations

% NK cellsa% CD16+ NK cells (MFI)b% NKG2D+ NK cells (MFI)c
PatientInfused cells1 week post-Rx PBMCPre-Rx PBMCInfused cells1 week post-Rx PBMCPre-Rx PBMCInfused cells1 week post-Rx PBMC
1979075 (534)ntd37 (136)79 (214)nt50 (130)
29691ntnt45 (172)ntnt59 (149)
3968668 (279)55 (125)42 (149)21 (79)100 (884)14 (66)
4987176 (325)33 (64)26 (44)42 (100)97 (440)18 (64)
5975577 (430)47 (129)16 (43)66 (149)100 (778)20 (65)
6939354 (271)nt35 (122)37 (96)nt29 (80)
7979391 (675)63 (213)65 (266)e53 (140)98 (540)36 (109)e
8958277 (610)42 (135)35 (108)78 (248)100 (1,572)62 (153)
  • a% NK cells in infused cell populations was determined by FACS as the % PI- CD3 CD56+ cells. % NK cells in posttreatment PBMC samples approximately 1 week after treatment (day 7 or 8) was determined by the Hematology and Immunology Flow Cytometry Laboratories within the Department of Laboratory Medicine at the NIH Clinical Center as the number of CD3 cells that expressed either CD56 or CD16 as a percentage of the ALC.

  • bCD16 expression on the indicated cell populations was evaluated by FACS after gating on CD3 CD56+ cells.

  • cNKG2D expression on the indicated cell populations was evaluated by FACS after gating on CD3 CD56+ cells.

  • d“nt” indicated not tested because of limited sample availability.

  • eFor patient 7, the 1-week posttreatment PBMC sample analyzed for CD16 and NKG2D expression was obtained 10 days after treatment because 7 or 8 day samples were not available.